Filing Analysis
MacroGenics amended its royalty purchase agreement with Sagard Healthcare Partners, securing an additional $60 million cash payment in exchange for royalty rights to ZYNYZ (retifanlimab-dlwr). This brings the total aggregate purchase price to $130 million, with a revised repayment cap and a potential $20 million milestone based on 2026 sales performance.
Key Facts
- Received an additional $60.0 million cash payment from Sagard on May 1, 2026.
- Total aggregate purchase price for ZYNYZ royalties increased from $70 million to $130 million.
- Royalty rights revert to MacroGenics once Sagard receives 1.70x of the aggregate price by September 30, 2032, or 2.0x thereafter.
- Eligible for a one-time milestone payment of up to $20.0 million based on ZYNYZ achieving specific 2026 net sales thresholds.
- MacroGenics retains other economic interests including future development, regulatory, and commercial milestones under its original agreement with Incyte Corporation.
MacroGenics announced that the U.S. FDA has removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab. This allows the company to resume full clinical development of the bispecific DART molecule for patients with gynecologic cancers.
Key Facts
- The FDA removed the partial clinical hold on April 8, 2026.
- The affected study is the Phase 2 LINNET trial.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study focuses on patients with gynecologic cancers.
MacroGenics, Inc. announced its financial and operating results for the fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
Key Facts
- The filing reports financial and operating results for the year ended December 31, 2025.
- The announcement was made on March 9, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A full press release is attached as Exhibit 99.1.
MacroGenics, Inc. announced that Class I director Jay Siegel, M.D. will not stand for re-election at the company's 2026 Annual Meeting of Stockholders. The departure is for personal reasons and does not involve any disagreements with the company.
Key Facts
- Jay Siegel, M.D. notified the Board of Directors on February 25, 2026, that he will not seek re-election.
- Dr. Siegel is a Class I director.
- The decision was cited as being for personal reasons.
- The company stated there were no disagreements regarding operations, policies, or practices.
MacroGenics announced that the FDA has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in patients with gynecologic cancers.
Red Flags
- FDA partial clinical hold indicates potential safety concerns or regulatory deficiencies.
- Significant risk to clinical development timelines for a key pipeline asset.
Key Facts
- The FDA issued a partial clinical hold on February 23, 2026.
- The affected study is the Phase 2 LINNET trial evaluating lorigerlimab.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study targets patients with gynecologic cancers.